May 8 |
Nuvectis Pharma Inc Reports Q1 2024 Financial Outcomes
|
May 7 |
Nuvectis Pharma Q1 EPS of -$0.25
|
May 7 |
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
|
Apr 17 |
Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
|
Apr 8 |
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
|
Apr 2 |
5 Healthcare Stocks to Buy for 2024
|
Mar 21 |
Insider Buys Additional US$51k In Nuvectis Pharma Stock
|
Mar 15 |
Nuvectis Pharma to Present at the 36th Annual Roth Conference
|
Mar 14 |
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
|
Mar 6 |
Nuvectis Pharma GAAP EPS of -$1.43 beats by $0.16
|